Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone

Table 2 Body composition, femur length, femur and whole body BMC and BMD

Group	Control (n = 12)	Fenofibrate (n = 11)	Pioglitazone (n = 8)
Body weight (g)	237 ± 14.9	243 ± 9.60	240 ± 8.70
Fat mass (g)	46.8 ± 13.7	41.2 ± 6.94	62.5 ± 8.42^**/###
Lean mass (g)	184 ± 7.73	195 ± 8.98**	171 ± 8.87^**/###
Femur length (cm)	33.9 ± 0.44	34.1 ± 0.53	33.5 ± 0.57
Femoral BMC (g)	3.56 ± 0.30	3.78 ± 0.28	3.39 ± 0.26^##
Femoral BMD (g/cm²)	0.245 ± 0.009	0.259 ± 0.001**	0.235 ± 0.001^###
Whole body BMC (g)	7.23 ± 0.36	7.36 ± 0.26	6.87 ± 0.40^*/##
Whole body BMD (g/cm²)	0.159 ± 0.008	0.157 ± 0.005	0.143 ± 0.002^***/###

BMC = bone mineral content, BMD = bone mineral density. Data is presented as mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001 significantly different compared to control, ^##P < 0.01, ^###P < 0.001 significantly different compared to fenofibrate-treated group.

ISSN: 1472-6823